Public Forum
Default group for all members. Biological family sometimes get you down? Come join your logical family!
Organizers:
- Organized by
-
-
New Cancer Drugs Help Fewer Than 2% of Patients
-
New Cancer Drugs Help Fewer Than 2% of Patients
I was listening to a podcast today discussing a real-world prospective study on repurposed drugs in cancer.
A very sad comment came from a man that shared that he lost his 41-year-old wife to cancer. They threw every standard treatment available at her, and her quality of life before she died was so awful… but repurposed drugs were never even mentioned. Not once. You can imagine how that feels now.
What made it hit even harder was the data being discussed. The study showed around 84% of patients experienced either stable disease or a reduction in tumour growth—real-world outcomes, not theory.
Then this new review from the IMA highlights something difficult to ignore: most newly FDA approved cancer drugs benefit fewer than 2% of patients, and many are targeted at very small patient groups.
Read the full review here: https://imahealth.org/new-review-finds-most-new-cancer-drugs-help-fewer-than-2-of-patients/
So on one side, you have a system producing highly targeted drugs with very limited reach… and on the other, existing, widely available drugs showing meaningful outcomes in a large proportion of patients, but still rarely part of the conversation.
Let’s hope that as we see more and more information getting onto different channels, people can start to demand this from their doctors, perhaps that drives the change we so desperately need to see in cancer treatment.
-
0 Replies
Sorry, there were no replies found.
Log in to reply.